Gemmell brings over 25 years of experience across the healthcare sector, having held leadership roles at firms including GoodRx, Capsule, and Havas Life. Her career centers on scaling organizations and navigating revenue models within payer, provider, and pharmaceutical markets. At Viking, she joins a board currently overseeing a robust pipeline, most notably the dual GLP-1 and GIP receptor agonist VK2735, which is currently undergoing Phase 3 clinical evaluation.

CEO Brian Lian highlighted Gemmell’s ability to translate scientific innovation into commercial performance as a key factor for this appointment. Her expertise in go-to-market strategies is expected to support Viking’s efforts to establish a foothold in the competitive obesity and metabolic disease landscape. Chairman Lawson Macartney noted that her commercial background complements the board's existing strength in pharmaceutical development, providing a necessary bridge as the company prepares its next-generation therapies for patients.